Pain during procedurea,b · people requesting a surgical abortion at 5+0 to 7+0 weeks' gestation
1 finding from 1 review
Health‐related quality of life · anemia in patients with rheumatoid arthritis
1 finding from 1 review
Hemoglobin (Hb) level at the end of the study · anemia in patients with rheumatoid arthritis
1 finding from 1 review
Fatigue ‐ not reported · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and drug reactions · anemia in patients with rheumatoid arthritis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
Very low
Withdrawals due to adverse events · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Lack of efficacy withdrawal · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to high blood pressure · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether initial infusion rate of intravenous acetylcysteine over 15 minutes changes hepatotoxicity compared with 60 minutes (very low certainty).
1 finding from 1 review
Any adverse event · people with paracetamol (acetaminophen) overdose
Initial infusion rate of intravenous acetylcysteine over 15 minutes may leads to lower any adverse event compared with 60 minutes (low certainty).
1 finding from 1 review
Normalcy of diet (mean worst ability to eat, 1 to 4 scale) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (mean worst ability to eat, 1 to 4 scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
4 findings from 1 review
RR 0.96 [0.88, 1.05]
4 studies · 655 participants
GRADE not reported
Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented
2 studies
GRADE not reported
RR 0.95 [0.90, 1.00]
2 studies · 374 participants
GRADE not reported
Show 1 more finding
Number of days in hospital · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days unable to take medicine orally · Adults with cancer receiving treatment
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to KGF were typically oral-related or skin-related; mostly mild to moderate with very few serious events; reporting poor and inconsistent, not appropriate to meta-analyse (SoF comments cell,…
16 studies
GRADE not reported
Quality of life · Adults with cancer receiving treatment
The review found no eligible studies for this question.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.89 [0.80, 0.99]
6 studies · 852 participants
Low
RR 0.91 [0.83, 1.00]
3 studies · 471 participants
Moderate
RR 0.56 [0.45, 0.70]
4 studies · 344 participants
Moderate
Oral pain · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral pain (mean worst pain, 0 to 10 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube or IV hydration) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube… compared with placebo; GRADE not reported.
1 finding from 1 review